Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria-tetanus-pertussis whole-cell and Haemophilus influenzae type b vaccine
- Development stage
- Approved
- Lead developer
- Immunobiological Technology Institute (Bio-Manguinhos), Oswaldo Cruz Foundation (Fiocruz)
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The diphtheria-tetanus-pertussis whole-cell and Haemophilus influenzae type b vaccine (DTP/Hib-BM) is a combined, multi-antigen biological vaccine developed by Bio-Manguinhos/Fiocruz in collaboration with Instituto Butantan in Brazil. It is a tetravalent combination vaccine containing whole-cell pertussis (*Bordetella pertussis*), diphtheria toxoid, tetanus toxoid, and *Haemophilus influenzae* type b (Hib) conjugate as its active components. The vaccine is indicated for the active immunization of infants against diphtheria, tetanus, pertussis (whooping cough), and invasive diseases caused by *Haemophilus influenzae* type b (such as meningitis and pneumonia). It has been evaluated in clinical trials in Brazil, demonstrating non-inferior immunogenicity, safety, and lot-to-lot consistency compared to reference vaccines, and is also used as a component of pentavalent formulations that include a hepatitis B antigen.
- Other names
- DTPw/HibDTPw-Hibdiphtheria-tetanus-pertussis-haemophilus b conjugate vaccineDTP-Hib
02
Targets
TLR2 (Toll-like Receptor 2)Diphtheria toxinETV6 (ETS variant transcription factor 6)TLR5TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on diphtheria-tetanus-pertussis whole-cell and Haemophilus influenzae type b vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria-tetanus-pertussis whole-cell and Haemophilus influenzae type b vaccine.